Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Travere Therapeutics (TVTX) Tops Q4 EPS by 31c
February 23, 2023 4:33 PM ESTTravere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of ($0.76), $0.31 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $56.99 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
... More